Jon Congleton
Algemeen Directeur bij MINERALYS THERAPEUTICS, INC.
Vermogen: 16 M $ op 30-04-2024
Profiel
Jon Congleton is currently the Chief Executive Officer & Director at Mineralys Therapeutics, Inc. and an Operating Partner at Catalys Pacific LLC.
Previously, he served as the President & Chief Executive Officer at Alpine Immune Sciences, Inc. and the President, Chief Executive Officer & Director at Ipi Legacy Liquidation Co. He also held the position of President, Chief Executive Officer & Director at Nivalis Therapeutics, Inc. from 2014 to 2017.
Prior to that, he worked as the Senior VP-Global Brand Strategic Marketing at Teva Pharmaceutical Industries Ltd.
and as the Vice President & General Manager at Teva Neuroscience, Inc. Mr. Congleton completed his undergraduate degree at Kansas State University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 15-03-2024 | 1 454 235 ( 2.93% ) | 16 M $ | 30-04-2024 |
Actieve functies van Jon Congleton
| Bedrijven | Functie | Begin |
|---|---|---|
| MINERALYS THERAPEUTICS, INC. | Algemeen Directeur | 01-11-2020 |
Catalys Pacific LLC
 Catalys Pacific LLC Investment ManagersFinance Catalys Pacific LLC (Catalys Pacific) is a venture capital firm founded in 2018 by BT Slingsby. The firm is headquartered in Cayman Islands. | Private Equity Investor | - |
Eerdere bekende functies van Jon Congleton
| Bedrijven | Functie | Einde |
|---|---|---|
| IPI LEGACY LIQUIDATION CO | Algemeen Directeur | 05-05-2020 |
Nivalis Therapeutics, Inc.
 Nivalis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nivalis Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in discovery, development, and commercialization of product for patients with cystic fibrosis. Its product includes N91115, a small molecule that addresses a defect in the cystic fibrosis transmembrane conductance regulator. The company was founded in 2008 and is headquartered in Boulder, CO. | Algemeen Directeur | 15-01-2017 |
| ALPINE IMMUNE SCIENCES, INC. | Algemeen Directeur | 01-01-2017 |
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Verkoop & Marketing | - |
Teva Neuroscience, Inc.
 Teva Neuroscience, Inc. Pharmaceuticals: MajorHealth Technology Teva Neuroscience, Inc. developed and marketed drugs for neurological disorders. The company's product COPAXONE was used to reduce relapses caused by relapsing-remitting multiple sclerosis. It also offered treatment for Parkinson's disease. Teva Neuroscience was founded in 1997 and was located in Kansas City, MO | Corporate Officer/Principal | - |
Opleiding van Jon Congleton
| Kansas State University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 4 |
|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Health Technology |
| IPI LEGACY LIQUIDATION CO | Health Technology |
| ALPINE IMMUNE SCIENCES, INC. | Health Technology |
| MINERALYS THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Teva Neuroscience, Inc.
Teva Neuroscience, Inc. Pharmaceuticals: MajorHealth Technology Teva Neuroscience, Inc. developed and marketed drugs for neurological disorders. The company's product COPAXONE was used to reduce relapses caused by relapsing-remitting multiple sclerosis. It also offered treatment for Parkinson's disease. Teva Neuroscience was founded in 1997 and was located in Kansas City, MO | Health Technology |
Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nivalis Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in discovery, development, and commercialization of product for patients with cystic fibrosis. Its product includes N91115, a small molecule that addresses a defect in the cystic fibrosis transmembrane conductance regulator. The company was founded in 2008 and is headquartered in Boulder, CO. | Health Technology |
Catalys Pacific LLC
Catalys Pacific LLC Investment ManagersFinance Catalys Pacific LLC (Catalys Pacific) is a venture capital firm founded in 2018 by BT Slingsby. The firm is headquartered in Cayman Islands. | Finance |
